Cargando…
Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction
AIMS: Murine models implicate phosphodiesterase 9A (PDE9A) as a nitric oxide‐independent regulator of cyclic guanosine monophosphate and promising novel therapeutic target in heart failure (HF) with preserved ejection fraction (HFpEF). This study describes PDE9A expression in endomyocardial biopsies...
Autores principales: | Besler, Christian, Rommel, Karl‐Philipp, Kresoja, Karl‐Patrik, Mörbitz, Justus, Kirsten, Holger, Scholz, Markus, Klingel, Karin, Thiery, Joachim, Burkhardt, Ralph, Büttner, Petra, Adams, Volker, Thiele, Holger, Lurz, Philipp |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120363/ https://www.ncbi.nlm.nih.gov/pubmed/33787083 http://dx.doi.org/10.1002/ehf2.13327 |
Ejemplares similares
-
Deep learning detects heart failure with preserved ejection fraction using a baseline electrocardiogram
por: Unterhuber, Matthias, et al.
Publicado: (2021) -
Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials
por: Kresoja, Karl-Patrik, et al.
Publicado: (2023) -
Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
por: Rosch, Sebastian, et al.
Publicado: (2020) -
Sympathomodulation in Heart Failure with High vs. Normal Ejection Fraction
por: Fengler, Karl, et al.
Publicado: (2022) -
Tubulin expression and modification in heart failure with preserved ejection fraction (HFpEF)
por: Schulz, Lisa, et al.
Publicado: (2022)